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wear, both of which induce an increase in the rate of axial
elongation, the percentage of glucagonergic amacrine cells
positively labeled for ZENK was significantly reduced. In
contrast, 2 h of either positive-lens wear or removal of
diffusers from previously form-deprived eyes, both of which
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Purpose: To examine in detail the time-course of changes in Zif268, Egr-1, NGFI-A, and Krox-24 (ZENK) and pre-
proglucagon (PPG) RNA transcript levels in the chick retina during periods of increased ocular growth induced by form-
deprivation and negative-lens wear. To further elucidate the role of ZENK in the modulation of ocular growth, we
investigated the effect of intravitreal injections of the muscarinic antagonist atropine and the dopamine agonist 2-
amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide (ADTN), both of which block the development of
experimental myopia, on the expression of ZENK in eyes fitted with negative-lenses.
Methods: Myopia was induced by fitting translucent diffusers or −10D polymethyl methacrylate (PMMA) lenses over
one eye of the chicken. At times from 1 h to 10 days after fitting of the diffusers or negative lenses, retinal RNA transcript
levels of the selected genes were determined by semi-quantitative real-time reverse transcriptase polymerase chain reaction
(RT–PCR). For the pharmacology experiments, −10D lenses were fitted over the left eye of chicks for a period of 1h.
Intravitreal injections of atropine (10 μl–25 mM), ADTN (10 μl–10 mM), or a vehicle solution were made immediately
before fitting of the lenses.
Results: ZENK RNA transcript levels were rapidly and persistently down-regulated following the attachment of the optical
devices over the eye. With a delay relative to ZENK, PPG transcript levels were also down-regulated. Induced changes
in gene expression were similar for both form-deprivation and negative-lens wear. When atropine or ADTN were
administered immediately before lens attachment, the rapid down-regulation in ZENK RNA transcript levels normally
seen following 1 h of negative-lens wear was not seen, and ZENK transcript levels rose above those values seen in control
eyes. However, injection of atropine or ADTN into untreated eyes had no effect on ZENK transcript levels.
Conclusions: Both form-deprivation and negative-lens wear modulated the retinal expression of ZENK and PPG RNA
transcripts, with a similar time-course and strength of response. The ability of the tested drugs to prevent the down-
regulation of ZENK in both lens-induced myopia (LIM) and form-deprivation myopia (FDM) suggests that atropine and
ADTN act directly and rapidly on retinal circuits to enhance sensitivity early in the signaling process. These findings
suggest that very similar molecular pathways are involved in the changes in eye growth in response to form-deprivation
and negative lenses at 1 h after the fitting of optical devices.Received: January 22, 2010Accepted: April 6, 2010
The emergence of a myopia epidemic in urban East Asia
(for review see Morgan and Rose [1]), has prompted
considerable research to understand the molecular pathways
involved in the regulation of ocular growth (for review see
[2]). It is generally believed that the pathways involved in the
control of eye growth involve signal cascades initiated in the
retina, which send signals through the retinal pigment
epithelium (RPE) and choroid to control the growth of the
sclera. However, the identities of the retinal molecules and
pathways involved are still unclear. Recent work has
investigated global changes in retinal gene expression during
the development of experimental myopia [3-8], giving some
insight into possible molecules involved in the regulation of
ocular growth.
Two important candidate molecules are the retinal
peptides, ZIF268, Egr-1, NGFI-A, or Krox-24 (ZENK) and
glucagon, which have previously been implicated in the
control of eye growth [3,9-11]. ZENK, is a member of the
immediate early gene (IEG) family of transcriptional
regulators, and is the avian ortholog of the IEG Egr-1. It
encodes for a short-lived nuclear protein with a zinc finger
binding domain. Its expression is normally rapidly and
transiently induced by extracellular stimuli. ZENK has been
implicated in the modulation of eye growth due to the
observation that the percentage of glucagon-immunoreactive
amacrine cells positively labeled for the ZENK peptide shows
a bi-directional response to opposing growth stimuli [9].
Following 30 min or 2 h of form-deprivation or negative-lens
reduce the rate of eye growth, caused a significant increase in
the percentage of glucagonergic amacrine cells positively
labeled for the ZENK peptide. Schippert et al. [12] have
reported a relative myopic shift in Egr-1 knockout mice as
compared to wild-type control animals, further supporting a
role for this IEG in growth modulation. At the RNA transcript
level, Simon et al. [13] have reported significant down-
regulation in ZENK levels following 30 min and 2 h of
negative-lens wear. The molecular studies have therefore only
examined relatively short exposure times, whereas
modulation of eye growth is prolonged.
To gain more detailed information on the coupling of
changes in ZENK and PPG RNA transcript levels with
changes in the rate of ocular growth stimulated by visual
manipulation, we studied the changes in transcript levels at
times from 1 h to 10 days, using the two paradigms that
promote axial elongation–form-deprivation myopia (FDM)
and lens-induced myopia (LIM). To analyze whether the eye
uses similar mechanisms in FDM and LIM, we compared the
changes in gene expression seen during the development of
FDM and LIM, and also compared the effects of atropine and
ADTN, both capable of retarding development of
experimental myopia in chicks [19], on early changes in
ZENK expression in the two paradigms.
METHODS
Animal housing: One-day-old male Australorp chickens were
obtained from Barter and Sons Hatchery, Luddenham, NSW,
Australia. Chickens were maintained in temperature-
controlled rooms under a 12:12 h light–dark cycle, with
incandescent illumination of ~500 lux during the light phase,
and <1 lux in the dark phase (lights on at 6 am and off at 6 pm).
Chickens had access to unlimited amounts of food and water,
and were given three days to become accustomed to their
surroundings before experiments were started. All
experiments were approved by the Australian National
University Animal Experimentation Ethics Committee
(Protocols R.VS.14.03 and R.VS.18.05) and conformed to the
ARVO Resolution on the Use of Animals in Ophthalmic and
Vision Research.
Experimental treatment – visual manipulation: The methods
used for induction of FDM, which results from increased axial
elongation of the eye, have been previously described in detail
[6,8]. Briefly, FDM was induced monocularly by fitting a
translucent diffuser over the left eye of 5-day-old chickens,
using Velcro® mounts. The diffusers were made from
Wellcome Codral® (Johnson and Johnson Pacific Pty Ltd,
Sydney, Australia) blister strips, and reduced light intensity
by ~0.4 log units. LIM, which also results from increased axial
elongation of the eye, was induced by fitting −10D PMMA
lenses over the left eye of five-day-old chickens, using similar
Velcro® mounts.
For the analysis of changes in gene expression during the
development of FDM (n=90) or LIM (n=90), five-day-old
chickens were exposed to the diffusers or negative lenses for
periods of 1 h or 1, 3, 7, or 10 days. For both FDM and LIM,
nine samples per experimental condition were collected at
each time point. Each sample contained two retinas from
experimental eyes, one from each of two animals. Retinas
from contralateral eyes were also collected, and processed
separately from internal contralateral controls. In parallel,
pooled retinas were collected from age-matched untreated
control animals (n=9) at each time point for all experimental
conditions.
Intravitreal injection protocol: Chickens were split into eight
groups: (1) injection of an atropine solution immediately
before fitting a negative lens (n=6), (2) injection of an atropine
vehicle solution (distilled water) immediately before fitting a
negative lens (n=6), (3) injection of an 2-amino-6,7–18
dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide
(ADTN) solution immediately before fitting a negative lens
(n=6), (4) injection of an ADTN vehicle solution (1% [w/v]
ascorbic acid) immediately before fitting a negative lens
(n=6), (5) no injection immediately before fitting a negative
lens (injection control, n=6), (6) injection of an atropine
solution into otherwise untreated eyes (n=6), (7) injection of
an ADTN solution into otherwise untreated eyes (n=6), and
(8) age-matched untreated control birds (n=6).
Negative 10D polymethyl methacrylate (PMMA) contact
lenses were fitted over the left eyes of chickens at 11 AM on
the day of treatment, using the methods described above. In
these experiments, lenses were attached for a period of 1 h
before the animals were euthanized and retinal tissue
collected.
Intravitreal injections into the lens-treated eyes were
performed immediately before the attachment of the lenses
under light isoflurane anesthesia (5% in 1 l of medical grade
oxygen per minute), using a handheld 0.3 ml BD Ultra-Fine
II syringe with a 8 mm long 31 gauge needle. The intraocular
injections consisted of 10 μl of either 25 mM atropine (Sigma-
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Glucagon is a 29-amino-acid long peptide produced by
the proteolytic cleavage of the precursor molecule pre-
proglucagon (PPG) [14]. Glucagon is part of a superfamily of
secretin-glucagon peptides that act through G-protein coupled
receptors, and has increasingly been identified as a possible
neurotransmitter in the central nervous system [15,16].
Exposure to negative lenses has been shown to increase
glucagon peptide levels, as measured by radioimmunoassay,
after 24 h but not after 4 h of lens wear [10]. At the RNA
transcript level, Buck et al. [11] reported that PPG levels were
initially upregulated following 2 h of negative-lens treatment,
before showing significant down-regulation after 24 h of lens
wear. It has also been demonstrated that glucagon agonists can
prevent experimentally induced myopia [17,18], while
glucagon antagonists can prevent compensation for positive-
lens wear [18], suggesting a role for glucagon in the
modulation of eye growth.
Aldrich, Castle Hill, NSW, Australia) dissolved in distilled
water (pH 7.4), 10 mM 2-amino-6,7-dihydroxy-1,2,3,4-
tetrahydronaphthalene hydrobromide (ADTN; Sigma-
Aldrich) dissolved in 1% ascorbic acid (pH 7.4), or distilled
water or 1% ascorbic acid as vehicles (pH 7.4), as appropriate.
Parallel experiments were performed on control birds that
were not exposed to any visual manipulation. One injection
per eye was made into the vitreous chamber through the sclera
in the superior-temporal corner of the eye, by pulling back the
eyelid and using an 8 mm long needle to inject into the middle
of the vitreous body, so that contact with the retina was
avoided. Due to the length of the needle and the angle of
insertion, it was not possible to strike the retina; therefore, we
did not monitor this process. However, when undertaking
dissections of each eye, no indication was seen that any of the
retina’s had been punched by a needle.
Tissue preparation: Chickens were euthanized with CO2.
Each eye was removed and hemisected equatorially, with the
anterior portion of the eye and vitreous body discarded. The
posterior eye cup was floated in chilled phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 11.3 mM Na2HPO4,
1.5 mM KH2PO4, pH 7.4), allowing collection of the retina
free of RPE, choroidal, and scleral tissue. Tissue was
immediately frozen on dry ice and then stored at −80 °C until
use.
Preliminary experiments (results not shown)
demonstrated that there were no significant diurnal rhythms
in the expression of ZENK or PPG RNA transcripts sampled
at 4 h intervals over a 24 h period, whereas rhythms were
detected in retinal clock gene period 2 (Per2) RNA transcript
expression, similar to those previously reported [20]. This
suggests that the time of collection of samples was not an
important factor, but, as an additional precaution, all samples
were collected between 12 noon and 2 PM
Preparation of RNA and reverse transcription to cDNA: The
methods used for the preparation of RNA, reverse
transcription, and quantification by real-time reverse
transcriptase (RT)–PCR using the combined Trizol®/Qiagen
RNeasy method have been previously described in detail [8,
21]. Total RNA purity was checked using gel electrophoresis,
and quantified using spectrophotometry. Samples (0.5 μg/μl)
were reverse-transcribed to first strand cDNA, which was
used as a cDNA template for real-time RT–PCR reactions,
using Taq DNA polymerase (Promega, Alexandria, NSW,
Australia). The primers used for the analysis of chicken ZENK
and PPG RNA transcript expression, as well as β-actin
(Actb), are shown in Table 1, and were validated through gel
electrophoresis and automated sequencing. Primer efficiency
(E) was determined from the slope of the curve generated
through a cDNA dilution series, using the formula E=10(−1/slope)
(Table 1).
Real-time RT–PCR: All reactions were performed on a
RotorGene 3000 RT–PCR cycler (Corbett Research,
Doncaster, Victoria, Australia). Cycling conditions included
an initial denaturing phase of 95 °C for 5 min, followed by 35
cycles of denaturation at 95 °C for 25 s, annealing at 60 °C
for 15 s, and extension at 72 °C for 20 s. Specificity of
amplification was confirmed through melt curve analysis and
gel electrophoresis of PCR products. Repeat takeoff values
and sample amplification values obtained by the RotorGene
v6.0 software were transferred into a custom-built Microsoft
Excel spread sheet. For graphical representation, the relative
expression ratio for each gene was determined by formula
[22], with values from age-matched untreated animals serving
as control values for determination of changes in gene
expression within experimental and contralateral control eyes.
The expression of target genes was normalized against the
reference gene Actb, with repeat takeoff values for Actb
unaffected by experimental treatments.
Refraction of chickens: Refraction was measured for treated
(n=8 per treatment group) and contralateral control eyes (n=8
per treatment group) daily over a ten-day period after fitting
the diffusers or lenses. If a diffuser or lens was dislodged or
removed by a bird, that animal was removed from the study.
Each chick was anaesthetized using isoflurane as described
above. The eyelids of the anaesthetized chick were held open
using forceps, while the refractive error was measured by
retinoscopy (Heine, Beta 200, Brookvale, NSW, Australia)
with wide aperture optical trial lenses. The refraction in each
meridian was measured. Refractions were corrected for the 33
cm working distance, and expressed as the spherical
equivalent.
Statistical analysis: Results are presented as mean plus or
minus standard error of the mean. Student t-tests and a
multivariate ANOVA (MANOVA) were performed using
JMP 7®, (SAS Institute GmbH, Munich, Germany) with the
TABLE 1. SEQUENCES, SLOPE, EFFICIENCY (E) AND R2 CORRELATION OF GENE-SPECIFIC PRIMERS USED FOR RT–PCR ASSAYS.
Gene product      GenBank                    Primer (5′-3′) size (bp) Slope Efficiency Correlation Product
Egr-1 AF026082 ACTAACTCGTCACATTCGCA -3.55 1.91 0.99 241
TGCTGAGACCGAAGCTGCCT
PPG NM_205260.1 AGCGTCATTCACAAGGCA -3.76 1.85 0.98 184
TCAGAATGACGCTTGGAAAT
Actb NM_205518 TAAGGATCTGTATGCCAACACAGT -3.48 1.94 0.99 241
GACAATGGAGGGTCCGGATTCATC
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cut-off for significance at the 5% confidence level. All other
calculations were performed in Microsoft® Excel 2003
(Microsoft Corporation, Redmond, WA).
For statistical analyses and graphical representation of
changes in ZENK and PPG RNA transcript expression, the
mean normalized expression (MNE) of the target genes was
calculated separately for each condition (treated, contralateral
control, and age-matched untreated control retinal tissue). The
MNE was calculated from the efficiency (E) of the target
genes to the power of its average crossing threshold (CT)
value (ECT target), divided by the efficiency (E) of the
reference gene (Actb) to the power of its average CT value
(ECT reference), following the method of Simon et al. [23]. A
MANOVA, followed by the student’s unpaired t-test with the
Bonferroni correction for multiple testing, was used to
compare the effects of different treatment regimes on the
MNE over time, and group changes at individual time points
on ZENK and PPG transcript levels. A MANOVA with repeat
measures design was used to analyze changes in ocular
refraction over time for each treatment regime.
RESULTS
Changes in refraction: As shown in Figure 1, at baseline, the
chickens had on average moderately hyperopic refractions
(+3.1±0.6 D), but they rapidly developed FDM, which
increased in magnitude over the 10 day experimental period
(MANOVA, repeated measures; F (1, 10)=25.8, p<0.0001;
Figure 1). In contrast, in the contralateral eyes, the initial
moderate hyperopia (+3.7±0.5 D) slowly decreased to a mean
refraction close to emmetropia over the experimental period
(+0.4±0.2 D; MANOVA, repeated measures; F (1, 10)=8.3,
p<0.01).
Chick eyes exposed to −10D lenses compensated over a
period of days for the imposed refractive error (Figure 1).
Specifically, by the seventh day of negative lens treatment, all
eyes had nearly compensated for the imposed hyperopic
defocus (−9.2±0.5D). The values plateaued over the
remaining three days of refractive measurements (day 8,
−9.8±0.4D; day 9, −9.7±0.3D; day 10, −9.8±0.2D).
Contralateral control eyes showed little change in refractive
error, displaying mild levels of hyperopia over the time-course
measured (MANOVA, repeated measures; F (1, 10)=0.34,
p=0.84; Figure 1). Although the changes in refraction of
contralateral control eyes appeared different between
treatment groups (e.g., FDM and LIM), this behavior was not
statistically significant over time (MANOVA, repeated
measures; F (1, 10)=2.04, p=0.18).
Changes in ZENK RNA transcript expression during
development of FDM and LIM: The fitting of translucent
diffusers or negative lenses significantly affected ZENK RNA
transcript levels in the experimental eyes over time, as
compared to both contralateral control values (MANOVA; F
(2,86)=33.9, p<0.01, and F (2,86)=32.9, p<0.001,
respectively) and age-matched untreated control values
(MANOVA; F (2,86)=37.9, p<0.001 and F (2,86)=18.5,
p<0.01, respectively). There was no significant difference
over time in expression of ZENK transcript levels between
contralateral control eyes, for either the form-deprived or the
negative-lens-treated animals and age-matched untreated
values (MANOVA; F (2,86)=2.65, p=0.14 and F (2,86)=0.69,
p=0.43, respectively).
ZENK RNA transcript levels in the retina were
significantly depressed following 1 h of form-deprivation (t-
Figure 1. Changes in the refractive error
of treated and contralateral control eyes
over ten days of form-deprivation and
negative-lens wear. The fitment of
translucent diffusers over the eye
induced significant development of
myopia over the ten-day experimental
period, as compared to control values
(MANOVA; F (1,10)=8.3, p<0.01).
Chicks fitted with −10D lenses
significantly compensated for the lenses
over the initial seven days of treatment
(MANOVA; F (1,7)=10.2, p<0.01),
before plateauing. Although changes in
refraction of contralateral control eyes
appeared different between treatment
groups, this behavior was not
statistically significant over time
(MANOVA; F (1,10)=2.04, p=0.18).
Error bars represent the standard error of
the mean (SEM), n=8 per time, per
experimental treatment.
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test; p<0.05; Figure 2) and remained depressed, compared to
control values, over the entire time-course. The levels of
ZENK in the contralateral control eye were not significantly
affected during the development of FDM. Analysis of ZENK
expression over a 12:12 h light–dark cycle indicated that once
ZENK expression had been rapidly suppressed following 1h
of form-deprivation, it did not recover during the subsequent
dark phase, and was still suppressed at the beginning of the
following light phase, compared to age-matched control
values (MANOVA; F (2,46)=23.45, p<0.001) and
contralateral control values (MANOVA; F (2,46)=13.34,
p<0.01; Figure 3).
ZENK RNA transcript levels in the retina were
significantly down-regulated 1h after fitting negative lenses
(t-test; p<0.05; Figure 2). ZENK levels further declined after
chicks were exposed to 1, 3, and 7 days of hyperopic defocus,
as compared to that of contralateral control eyes (t-test;
p<0.05, p<0.01, and p<0.05, respectively) and age-matched
untreated eyes (t-test; p<0.05, p<0.01, and p<0.05,
respectively), before showing a return toward baseline levels
at day 10 of lens treatment (t-test; p=0.09).
Changes in PPG RNA transcript expression during the
development of FDM and LIM: The fitting of translucent
diffusers or negative lenses significantly affected PPG RNA
transcript levels in the experimental eye over time, as
compared to both contralateral control values (MANOVA; F
(2,86)=13.29, p<0.05 and F (2,86)=8.31, p<0.05,
respectively) and age-matched untreated control values
(MANOVA; F (2,86)=13.02, p<0.05 and F (2,86)=9.12,
p<0.05, respectively). There was no significant difference
over time in the expression of PPG transcript levels between
contralateral control eyes, in either form-deprived animals or
negative-lens-treated animals, and age-matched untreated
values (MANOVA; F (2,86)=0.27, p=0.62 and F (2,86)=0.10,
p=0.84, respectively).
PPG RNA transcript levels in the retina were not
significantly affected by 1h of form-deprivation (t-test;
p=0.61; Figure 4). However, after one day of diffuser wear,
PPG expression was significantly down-regulated (t-test,
p<0.05), and remained so for the duration of the form-
deprivation period (t-test; 3 days p<0.05, 7 days p<0.01, and
10 days p<0.05). The expression of retinal PPG transcripts in
the contralateral control eye was not significantly different
from that seen in age-matched control eyes at any point during
the development of FDM (Figure 4).
During the development of LIM, PPG transcript levels in
the retina showed a delayed but similar trend to that of ZENK
levels (Figure 4). The expression of PPG was significantly
down-regulated to below the levels seen in both contralateral
control (t-test; p<0.05) and age-matched untreated eyes (t-test;
p<0.05) after one day of lens wear. PPG expression further
declined over the following six days of lens treatment (t-test;
Figure 2. Changes in ZENK RNA transcript levels in treated and contralateral control retinas following increased ocular growth induced by
the fitting of translucent diffusers or negative lenses. Mean normalized expression of ZENK RNA transcript levels from diffuser-treated (A)
or negative-lens-treated (B) eyes following 1 h, 1, 3, 7, and 10 days of treatment. Fitting of translucent diffusers or negative lenses significantly
affected ZENK RNA transcript levels in the experimental eye over time, as compared to both contralateral control values (MANOVA; F
(2,86)=33.9, p<0.01 and F (2,86)=32.9, p<0.001, respectively) and age-matched untreated control values (MANOVA; F (2,86)=37.9, p<0.001
and F (2,86)=18.5, p<0.01, respectively). ZENK transcript levels in the contralateral control eyes from either form-deprived or negative-lens-
treated animals were unaffected by treatment as compared to age-matched untreated values (MANOVA; F (2,86)=2.65, p=0.14 and F
(2,86)=0.69, p=0.43, respectively). The mean normalized expression is calculated from the efficiency (E) of the target genes to the power of
its average CT value (ECT, target), divided by the efficiency (E) of the reference gene (β-actin) to the power of its average CT value (ECT,
reference). Error bars represent SEM, n=9. (* p<0.05, ** p<0.01).
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3 days p<0.05 and 7 days p<0.01), before returning to control
levels by day 10 of lens wear (t-test; p=0.39).
Changes in ZENK expression in negative-lens-treated eyes
following atropine or ADTN treatment: ZENK transcript
levels were significantly down-regulated after 1h of negative-
lens wear as compared to untreated control values (ANOVA;
F (4,20)=4.24, p<0.05; t-test, p<0.05). This down-regulation
was unaffected by injection of either vehicle solution (t-test;
water, p=0.70; ascorbic acid, p=0.80; Figure 5). In contrast,
the injection of the muscarinic cholinergic antagonist atropine
or the dopamine agonist ADTN, immediately before the
fitting of negative lenses, prevented the down-regulation in
ZENK transcript levels observed after 1 h of negative-lens
wear alone (ANOVA; F (3,14)=6.32, p<0.05; t-test, p<0.05),
with ZENK levels rising above those seen in age-matched
untreated eyes (ANOVA; F (3,14)=4.89, p<0.05; t-test;
p<0.05). The injection of atropine or ADTN into control eyes
not treated with negative lenses had no effect on the retinal
expression of ZENK (ANOVA; F (3,14)=0.78, p=0.11; t-test;
p=0.15 and p=0.10, respectively). Thus, ZENK RNA
transcript levels in the retina were increased by atropine and
ADTN only in circumstances that lead to suppression of
excessive axial elongation.
DISCUSSION
Changes in ZENK and PPG RNA transcript levels during
periods of increased ocular growth: During periods of
increased ocular growth induced by form-deprivation or
negative lenses, ZENK transcript levels in the retina were
rapidly suppressed, consistent with the changes observed at
the peptide level by Fischer et al. [9] and at the RNA transcript
level by Simon et al. [13], for negative-lens treatment. This
down-regulation, however, was not transient, as ZENK
expression remained down-regulated for much of the FDM
and LIM treatment period.
The shape of the changes in ZENK transcript expression
induced by imposed hyperopic defocus differed from that seen
during development of FDM, which may be related to
differences in the rate of ocular growth over the experimental
period. Specifically, by day 7 of treatment, most chicks had
fully compensated for the negative lenses, with a
corresponding return of ZENK expression to baseline levels.
In contrast, chicks that wore diffusers showed elevated levels
of ocular growth over the entire ten days of treatment, with a
corresponding continued reduction in ZENK expression.
The expression of IEGs such as ZENK are normally low
in non-stimulated cells, but following external stimulation,
their transcription is rapidly, and usually transiently,
upregulated (for review see [24]). In contrast, the loss of form-
vision or the attachment of negative lenses produced a rapid,
yet prolonged, down-regulation in ZENK transcript levels.
Morgan and Curran [25] have postulated that there are at least
three broad categories of IEG response to external stimuli–the
Figure 3. Changes in ZENK RNA
transcript levels in the chick retina over
a 24 h time period. ZENK transcript
levels in the retina were significantly
suppressed following 1 h of form-
deprivation, and remained suppressed
during the subsequent dark phase and
the beginning of the following light
phase, as compared to age-matched
control values (ANOVA; F
(2,46)=23.45, p<0.001) and
contralateral control values (ANOVA; F
(2,46)=13.34, p<0.01). The mean
normalized expression is calculated
from the efficiency (E) of the target
genes to the power of its average CT
value (ECT, target), divided by the
efficiency (E) of the reference gene (β-
actin) to the power of its average CT
value (ECT, reference). Error bars
represent SEM, n=5.
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classical rapid and transient upregulation of IEGs; a delayed,
yet prolonged, increase in gene expression; and a continuous
tissue-specific expression of IEGs. The prolonged depression
of ZENK in response to form-deprivation and negative lenses
is therefore unusual. The prolonged depression could be
explained by a renewed transient down-regulation in the
ZENK transcript levels each day at the onset of light, and a
new experience of form-deprivation or hyperopic defocus. A
more detailed time-course over a light–dark cycle, however,
reveals that the down-regulation of ZENK levels in the retina
is continuous over subsequent periods of light and dark
(Figure 3).
The prolonged down-regulation is also unlikely to be due
to the slight reduction in light intensity (~0.4 log units) caused
by the diffusers, since the fitting of negative lenses, which
produces little change in light intensity, induces a similar
suppression in ZENK levels in the retina. Overall, it appears
that during periods of increased axial growth, induced by
either the loss of form-vision or hyperopic defocus, ZENK
RNA transcript levels in the retina are rapidly suppressed, and
appear to remain down-regulated for the period of increased
ocular growth. The return of ZENK expression to control
levels at around the time when the imposed refractive error
has been neutralized in the LIM paradigm may be particularly
significant.
Changes in ZENK transcript expression were followed by
a slower but similar change in retinal PPG transcript levels
during both FDM and LIM. The initial increase in expression
reported by Buck et al. [11] was not observed in this study.
PPG expression in the retina returned to baseline levels
following ten days of negative lens treatment, when the
imposed refractive error had been largely compensated for. In
contrast, following a similar period of form-deprivation, the
rate of ocular growth would still have been elevated and the
retinal expression of glucagon was still down-regulated. In
general, changes in both ZENK and PPG transcript levels
correlated well with the refractive changes observed during
negative-lens compensation.
The pattern of changes observed is consistent with a
pathway in which down-regulation of ZENK expression is
followed by the down-regulation of the expression of PPG
transcripts. Down-regulation of gene expression for the
precursor of a peptide hormone/transmitter such as glucagon
is most likely indicative of a reduced rate of synthesis of the
peptide precursor, and of a decreased rate of glucagon release
during the development of experimental myopia [26]. The
Figure 4. Changes in pre-proglucagon RNA transcript levels in treated and contralateral control retinas during periods of increased ocular
growth induced by the fitment of translucent diffusers or negative lenses. Mean normalized expression of PPG RNA transcript levels from
diffuser-treated (A) and negative-lens treated (B) eyes following 1 h, 1, 3, 7, and 10 days of treatment. The fitting of translucent diffusers or
negative lenses significantly affected PPG RNA transcript levels in the experimental eye over time, as compared to both contralateral control
values (MANOVA; F (2,86)=13.29, p<0.05 and F (2,86)=8.31, p<0.05, respectively) and age-matched untreated control values (MANOVA;
F (2,86)=13.02, p<0.05 and F (2,86)=9.12, p<0.05, respectively). There was no significant difference in the expression of PPG transcript
levels over time, between contralateral control eyes from either form-deprived animals or negative-lens-treated animals and age-matched
untreated values (MANOVA; F (2,86)=0.27, p=0.62 and F (2,86)=0.10, p=0.84, respectively). The mean normalized expression is calculated
from the efficiency (E) of the target genes to the power of its average CT value (ECT target), divided by the efficiency (E) of the reference
gene (β-actin) to the power of its average CT value (ECT reference). Error bars represent SEM, n=9. (* p<0.05, ** p<0.01).
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ability of glucagon agonists to block experimental myopia
[10,18] is consistent with such a pathway.
Expression of ZENK in negative-lens-treated eyes following
injection of atropine and ADTN: We have previously shown
that the intravitreal injection of atropine or ADTN into the
chick eye immediately before fitting diffusers prevents the
down-regulation in ZENK RNA transcript levels normally
observed after 1h, and in fact increased the levels of ZENK to
above control levels [8]. Very similar results were obtained
with the LIM paradigm. The ability of atropine and ADTN to
upregulate ZENK expression is in line with the known
induction of ZENK expression in the central nervous system
by both muscarinic cholinergic antagonists [27,28] and
dopaminergic agonists [29-33]. These results have several
implications. They add to the evidence that upregulation of
ZENK RNA or protein expression in the avian retina generally
correlates with reduction in the rate of ocular growth, induced
by the removal of diffusers from eyes subjected to prolonged
form-deprivation or the wearing of positive lenses [9], or by
the injection of atropine or ADTN into eyes developing
myopia [8]. As with form-deprivation [8], the down-
regulation of ZENK RNA transcript expression in the retina,
induced by negative-lens wear, was extremely rapid on a
biochemical timescale, with around a 40% reduction in levels
of RNA transcripts within 1 h. Similarly, the reversal of this
pattern of ZENK down-regulation by the injection of atropine
or ADTN was also observed within 1 h, demonstrating that
both compounds are capable of rapidly influencing one of the
earliest known molecular changes observed in the retina
during development of experimental myopia. Little is
currently known about retinal interactions between
cholinergic, dopaminergic, and glucagonergic cells in the
avian retina, although Fischer et al. [34] have reported
localization of the muscarinic-cholinergic receptor cm4 on all
amacrine cells immunoreactive for tyrosine hydroxylase.
As previously discussed in relation to FDM [8], the
differential effects of atropine and ADTN on ZENK RNA
transcript levels in the retina and on longer-term eye growth,
depending on whether or not lenses were fitted, suggest that
a profound change is induced in the functioning of the retinal
circuitry within the first hour, and probably within minutes,
of exposure to form-deprivation or lens-induced hyperopic
defocus. This suggests that the pathways involved in ‘normal’
eye growth, and those operating under conditions of
Figure 5. The effect of atropine and
ADTN on ZENK transcript levels in the
retina following 1 h of negative-lens
wear. Negative-lens wear, for a period
of 1h, induced significant down-
regulation in ZENK transcript levels
(ANOVA; F (4, 20)=4.24, p<0.05; t-
test, p<0.05, respectively), as compared
to normal untreated values, which was
unaffected by the injection of either
vehicle solution (distilled waster or
ascorbic acid) immediately before lens
fitting (t-test; p=0.7 and p=0.8,
respectively). However, injection of
atropine or ADTN immediately before
the attachment of lenses induced
significant upregulation in retinal ZENK
expression above baseline levels
(ANOVA; F (3, 14)=6.32, p<0.05; t-
test, p<0.05, respectively). Atropine or
ADTN did not affect retinal ZENK
expression when injected into a normal
untreated age-matched eye (ANOVA; F
(3,14)=0.78, p=0.11; t-test, p=0.15,
p=0.10, respectively). The mean
normalized expression is calculated
from the efficiency (E) of the target
genes to the power of its average CT
value (ECT target), divided by the
efficiency (E) of the reference gene
(Actb) to the power of its average CT
value (ECT reference). Error bars
represent SEM, n=6 (*p<0.05).
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‘abnormal’ eye growth, are different in relation to the function
of dopaminergic and cholinergic circuits in the retina within
one hour of fitting the optical devices. Similarly, as previously
discussed in relation to FDM, the speed of change at the retinal
level in both FDM and LIM, in response to atropine and
ADTN, suggests that these compounds are acting at retinal
sites. Based on the current results we obviously cannot
exclude other sites of action. Such sites include the choroid
and RPE, which also show rapid changes during periods of
altered ocular growth, particularly since there are also
dopaminergic and muscarinic cholinergic pathways within
these tissues [34-39], as well as the sclera, which is known to
be affected directly by muscarinic antagonists [40,41]. But, if
the effects of the drugs were exerted at non-retinal sites, there
would need to be a rapid initiation of response outside the
retina, as well as rapid transmission of this response to sites
in the retina, to reverse in sign the retinal changes in levels of
ZENK mRNA within 1 h. We therefore believe that the most
plausible interpretation of our results is that atropine and
ADTN act at retinal sites, but we recognize that the arguments
are not conclusive. Work using a cholinotoxin and quisqualic
acid to disrupt cholinergic pathways in the retina [42] has been
interpreted as indicating that cholinergic amacrine cells are
not critical for the control of eye growth. However, lesioning
techniques are limited by the effectiveness of the toxins, and
we believe that the current study provides stronger evidence
in favor of retinal sites of action.
Is the response of the eye to form-deprivation and hyperopic
defocus modulated by similar underlying mechanisms?:
Irrespective of the implications for sites of action of atropine
and ADTN, a striking aspect of the pharmacological results,
in conjunction with the time-course data discussed above, is
the parallel between the molecular changes observed in
response to lens-induced myopia and to form-deprivation.
Although the morphological changes during the development
of FDM and LIM are similar, animal studies have indicated
that the underlying mechanisms may be different, due to
differences in the time-course of changes in axial length
[43], the effect of constant light [43] and brief periods of
stroboscopic illumination [44], the effect of optic nerve
sectioning [45], electroretinogram responses [46], and the
effect of the dopaminergic toxin 6-hydroxydopamine (6-
OHDA) [47]. However, more recent work has questioned
these initial conclusions in relation to the effect of optic nerve
sectioning [48], the effect of constant light [49], and the effect
of 6-OHDA [50]. Further similarities are that both are blocked
by the muscarinic antagonists atropine [51-53] and
pirenzepine [54,55], the dopamine agonist apomorphine [52],
the dopamine toxin 6-OHDA [47,50], reserpine (which
depletes serotonin and dopamine vesicle stores) [56], the nitric
oxide synthase inhibitor L-NAME [57,58], the glucagon
agonist Lys17,18, Glu21-glucagon [10,59,60], and nitric
oxide synthase (NOS) inhibitors [57,58]. In this paper, we
show that the molecular changes in expression of ZENK and
PPG are similar in FDM and LIM, and that both FDM and
LIM appear to produce similar changes in retinal circuitry that
increase the sensitivity of retinal circuits to dopaminergic
agonists and muscarinic cholinergic antagonists within 1 h of
the commencement of visual manipulation. There are,
however, some remaining differences reported between these
two paradigms [43,46], which require further investigation.
Contralateral effects: Several studies have observed similar
but less-pronounced changes in gene and peptide expression
in the contralateral control eye, compared to those seen in the
treated eye (see, for example [9,13,61-63]), and several
possible mechanisms for these changes have been discussed
[9]. In this study we did not find significant effects of the
experimental manipulations in one eye on ZENK or PPG
transcript levels in the contralateral eyes of treated animals at
any point within the time-course investigated. However, it
should be noted that there was some difference in the changes
in refraction in contralateral eyes of FDM birds, namely a
decline in hyperopia toward emmetropia, as compared to the
changes in contralateral eyes of LIM birds where the initial
hyperopic refraction was maintained. This issue also merits
further systematic investigation, since contralateral changes
in gene expression without changes in eye growth, or
contralateral changes in eye growth without changes in gene
expression, would raise serious questions about the causal
relationships involved.
In summary, the results of this gene study support the idea
that ZENK expression and the synthesis and release of
glucagon may be important in the control of eye growth, and
that changes in these two parameters may be related.
Furthermore, injection of the non-specific muscarinic
cholinergic antagonist atropine, and the non-specific
dopaminergic agonist ADTN, prevents the rapid down-
regulation in ZENK RNA transcript levels in the retina during
the development of experimental myopia, induced by either
negative-lens wear or form-deprivation, and in fact leads to
marked increases in ZENK mRNA expression. Therefore,
both atropine and ADTN appear to act on one of the earliest
retinal signals produced during periods of increased ocular
growth. The similar responses of retinal ZENK and PPG RNA
transcript levels in FDM and LIM are consistent with
substantial similarities in the cellular and molecular pathways
underpinning these two forms of experimental myopia.
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